Combating pancreatic cancer chemoresistance by triggering multiple cell death pathways

Area of Science:

• Oncology
• Molecular Biology
• Cell Death Pathways

Background:

• Pancreatic cancer is a leading cause of cancer death, with increasing incidence and mortality.
• Chemotherapy resistance in pancreatic tumors, stemming from cellular heterogeneity, significantly limits treatment efficacy.
• Tumor cell heterogeneity leads to varying sensitivities to chemotherapeutic agents among different clones within the same tumor.

Purpose of the Study:

• To explore novel therapeutic targets for pancreatic ductal adenocarcinoma (PDAC).
• To investigate strategies for overcoming chemoresistance in pancreatic cancer.
• To identify compounds that can induce various cell death pathways and reduce treatment resistance.

Main Methods:

• Focus on targeting mitochondria, which regulate key cell death signaling pathways.
• Investigating new compounds for their efficacy alone or in combination.
• Analyzing the role of cellular heterogeneity in chemoresistance.

Main Results:

• Mitochondria are identified as crucial regulators of cell death pathways (apoptosis, necroptosis, autophagy, ferroptosis, parthanatos).
• New compounds are being identified that show potential in targeting PDAC cell resistance.
• Combinatorial treatments targeting mitochondria may overcome existing resistance mechanisms.

Conclusions:

• Targeting mitochondria presents a promising avenue for overcoming pancreatic cancer chemoresistance.
• Developing new compounds and combination therapies that induce cell death is critical for future PDAC treatments.
• Addressing cellular heterogeneity and targeting mitochondria could be key to improving patient outcomes in pancreatic cancer.